- Home
- NYT vs BPMC Comparison
NYT vs BPMC Comparison
Compare NYT & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- BPMC
- Stock Information
- Founded
- NYT 1851
- BPMC 2008
- Country
- NYT United States
- BPMC United States
- Employees
- NYT N/A
- BPMC N/A
- Industry
- NYT Newspapers/Magazines
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- NYT Consumer Discretionary
- BPMC Health Care
- Exchange
- NYT Nasdaq
- BPMC Nasdaq
- Market Cap
- NYT 8.7B
- BPMC 5.8B
- IPO Year
- NYT N/A
- BPMC 2015
- Fundamental
- Price
- NYT $48.11
- BPMC $89.38
- Analyst Decision
- NYT Buy
- BPMC Buy
- Analyst Count
- NYT 6
- BPMC 20
- Target Price
- NYT $55.33
- BPMC $125.00
- AVG Volume (30 Days)
- NYT 1.9M
- BPMC 1.0M
- Earning Date
- NYT 05-07-2025
- BPMC 05-01-2025
- Dividend Yield
- NYT 1.50%
- BPMC N/A
- EPS Growth
- NYT 26.43
- BPMC N/A
- EPS
- NYT 1.77
- BPMC N/A
- Revenue
- NYT $2,558,919,000.00
- BPMC $508,824,000.00
- Revenue This Year
- NYT $8.41
- BPMC $45.43
- Revenue Next Year
- NYT $5.95
- BPMC $32.80
- P/E Ratio
- NYT $27.03
- BPMC N/A
- Revenue Growth
- NYT 6.66
- BPMC 104.04
- 52 Week Low
- NYT $41.55
- BPMC $80.68
- 52 Week High
- NYT $58.16
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- NYT 45.98
- BPMC 43.48
- Support Level
- NYT $46.97
- BPMC $84.59
- Resistance Level
- NYT $50.15
- BPMC $90.00
- Average True Range (ATR)
- NYT 1.14
- BPMC 3.42
- MACD
- NYT 0.25
- BPMC 0.16
- Stochastic Oscillator
- NYT 58.44
- BPMC 51.11
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the major source of revenue for both segments is subscription.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.